RecruitingNot ApplicableNCT05782777

Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial

Sponsor

Yonsei University

Enrollment

4,310 participants

Start Date

Apr 7, 2023

Study Type

INTERVENTIONAL

Conditions

Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation

Summary

This study sought to evaluate whether ezetimibe combination to high-intensity statin therapy will have more prominent beneficial effect compared to high-intensity statin monotherapy in patients who underwent coronary revascularization with newer generation drug-eluting stent (DES) implantation. Furthermore, the optimal OCT-based optimal expansion criteria as well as the efficacy and safety of newer generation will be investigated.

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg) and a drug called high-intensity statin monotherapy (atoravastatin 40mg) for people with coronary artery disease requiring coronary revascularization with newer generation des implantation. The study is currently recruiting participants at 1 location. People eligible for this study include aged 19 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg)

The initial dose of lipid-lowering therapy will be ezetimibe 10mg plus atoravastatin 40mg. During follow-up, the dose of ezetimibe 10mg plus atoravastatin 40mg is strongly recommended to be maintained.

DRUGhigh-intensity statin monotherapy (atoravastatin 40mg)

The initial dose of lipid-lowering therapy will be atoravastatin 40mg. During follow-up, the dose of atoravastatin 40mg is strongly recommended to be maintained.

Locations(1)

Yonsei University Health System, Severance Hospital

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05782777